Full Press Release Details
updated odronextamab data from relapsed refractory diffuse large b cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long term out.
REGN
updated odronextamab data from relapsed refractory diffuse large b cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long term out
Key Takeaway: updated odronextamab data from relapsed refractory diffuse large b cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long term out